Stocks · News reference
Inogen (NASDAQ:INGN) lowers FY2026 sales outlook from $366.000 million-$373.000 million to $355.000 million-$361.000 million vs $369.267 million estimate.
Reference details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
The health care sector's oversold stocks present buying opportunities for undervalued companies. RSI compares stock strength on up and down days, with an RSI below 30 considered oversold.
Read original at benzingaInogen (NASDAQ:INGN) sees Q3 sales of $92.400 million vs $98.967 million analyst estimate.
Read original at benzingaInogen (NASDAQ:INGN) reported quarterly sales of $95.084 million which missed the analyst consensus estimate of $95.233 million by 0.16 percent. This is a 3.04 percent increase over sales of $92.277 million the same
Read original at benzinga